Kridin K, Brüggen MC, Chua SL, et al. - This study's findings suggest that treatment strategies for Stevens-Johnson syndrome and toxic epidermal necrolysis differ across Europe, emphasising the importance of prospective therapeutic studies and registries.

• This cohort study involved 212 patients (134 of 211 [63.7%] women; mean [SD] age, 51.0 [19.3] years).

• It was noted that the mean (SD) body surface area detachment was 27% (32.8%).

• A culprit drug was found in 176 (83.0%) of the patients.

• Antibiotics were the most commonly suspected agents, followed by anticonvulsants, nonsteroidal anti-inflammatory drugs, allopurinol, and sulfonamides.

• Treatment options included systemic glucocorticoids, intravenous immunoglobulins, cyclosporine, and antitumor necrosis factor agents, as well as best supportive care.

• The majority of patients (63.7%) experienced severe acute-phase complications.

• The mortality rate after 6 weeks was 20.8%.

• Maximal body surface area detachment (≥ 30%) was found to be independently correlated with severe acute-phase complications and Score of Toxic Epidermal Necrolysis greater than or equal to 2 was significantly related to mortality.

• Cyclosporine was linked to a greater than or equal to 20% increase in body surface area detachment in the acute phase, as well as an increased risk of infections.

• The use of systemic glucocorticoids and intravenous immunoglobulins were linked to a lower risk of infection.

• There was no statistically significant difference in 6-week mortality between treatment groups.